Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy

Author
McCann, Liza
Kingsbury, Daniel
Joos, Rik
Houghton, Kristin
Terreri, Maria
Harel, Liora
Gerloni, Valeria
Schneider, Rayfel
Rutkowska-Sak, Lidia
Ruperto, Nicolino
Brachat, Arndt H.
Grom, Alexei A.
Wulffraat, Nico
Brunner, Hermine I.
Quartier, Pierre
Brik, Riva
Ozdogan, Huri
Nirmala, Nanguneri R.
Lovell, Daniel J.
Martini, Alberto
Abrams, Ken
Gram, Hermann
Valentin, Marie-Anne
Schumacher, Martin
Bek, Stephan
Lopez-Benitez, Jorge M.
Metadata
Show full item record
Abstract
Background: Canakinumab is a human anti-interleukin-1 beta (IL-1 beta) monoclonal antibody neutralizing IL-1 beta-mediated pathways. We sought to characterize the molecular response to canakinumab and evaluate potential markers of response using samples from two pivotal trials in systemic juvenile idiopathic arthritis (SJIA).
URI
http://hdl.handle.net/20.500.12627/93236
https://doi.org/10.1186/s13075-016-1212-x
Collections